Biotech clusters with patent strategies are more attractive to big pharma

Life sciences and biotech research clusters across the UK are benefiting from an improved funding climate and on-going consolidation in the pharmaceutical sector, but those with strategic intellectual property plans are likely to find favor with big pharma, according to Withers & Rogers patent and trade mark attorneys.

Improving access to venture capital in particular, is allowing biotech companies to take their research past the initial stages and turn it into an attractive investment proposition for big pharma. However, strategic intellectual property plans are critical and underpin any investment decision.